Compare MYND & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MYND | MDCX |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 16.6M |
| IPO Year | 2017 | N/A |
| Metric | MYND | MDCX |
|---|---|---|
| Price | $0.30 | $0.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 6.5K | ★ 2.6M |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.25 |
| 52 Week High | $1.15 | $8.90 |
| Indicator | MYND | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 37.04 | 40.15 |
| Support Level | $0.29 | $0.29 |
| Resistance Level | $0.36 | $0.36 |
| Average True Range (ATR) | 0.02 | 0.03 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 29.43 | 47.16 |
Mynd.ai Inc is a company that provides a platform for delivering digital content in K-12 classrooms, giving teachers seamless connectivity to inspire young minds. It features agnostic hardware that integrates across technology providers. Its product line includes a wide range of interactive tools and technologies, with its award-winning interactive displays at the forefront. It also offers interactive software apps such as Screen Share, computing modules, and accessories that meet the needs of customers, including K -12 educators, colleges and universities, small businesses and corporations, government agencies, and more. Geographically, it operates in United States and Rest of the world.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.